BACKGROUND: The mortality rate from respiratory syncytial virus (RSV) bronchiolitis has significantly reduced over the last decade. A major concern now is the long-term respiratory morbidity following RSV bronchiolitis. METHODS: In this prospective study, we randomly assigned 49 previously healthy infants with severe RSV bronchiolitis, early in the course of illness (< 5 days duration), to receive either conservative treatment (n = 21) oradditional ribavirin treatment (n = 24). Both groups were closely matched for age and clinical characteristics. RESULTS: During a prospective, closely monitored, 1-year follow-up period, the group treated with ribavirin had significantly fewer episodes (2.7 +/- 2.3 episodes vs 6.4 +/- 4.2 episodes per patient per year) and reduced severity of reactive airway disease (0.08 episodes vs 1.09 episodes of moderate-to-severe illness per patient per year) and respiratory illness-related hospitalization (25 hospital days vs 90 hospital days per 100 patients per year). CONCLUSIONS: Early ribavirin treatment of RSV bronchiolitis in previously healthy infants resulted in reduction of incidence and severity of reactive airway disease as well as respiratory illness-related hospitalization.
RCT Entities:
BACKGROUND: The mortality rate from respiratory syncytial virus (RSV) bronchiolitis has significantly reduced over the last decade. A major concern now is the long-term respiratory morbidity following RSV bronchiolitis. METHODS: In this prospective study, we randomly assigned 49 previously healthy infants with severe RSV bronchiolitis, early in the course of illness (< 5 days duration), to receive either conservative treatment (n = 21) or additional ribavirin treatment (n = 24). Both groups were closely matched for age and clinical characteristics. RESULTS: During a prospective, closely monitored, 1-year follow-up period, the group treated with ribavirin had significantly fewer episodes (2.7 +/- 2.3 episodes vs 6.4 +/- 4.2 episodes per patient per year) and reduced severity of reactive airway disease (0.08 episodes vs 1.09 episodes of moderate-to-severe illness per patient per year) and respiratory illness-related hospitalization (25 hospital days vs 90 hospital days per 100 patients per year). CONCLUSIONS: Early ribavirin treatment of RSV bronchiolitis in previously healthy infants resulted in reduction of incidence and severity of reactive airway disease as well as respiratory illness-related hospitalization.
Authors: Eric A F Simões; Louis Bont; Paolo Manzoni; Brigitte Fauroux; Bosco Paes; Josep Figueras-Aloy; Paul A Checchia; Xavier Carbonell-Estrany Journal: Infect Dis Ther Date: 2018-02-22
Authors: Sebastien Kenmoe; Etienne Atenguena Okobalemba; Guy Roussel Takuissu; Jean Thierry Ebogo-Belobo; Martin Gael Oyono; Jeannette Nina Magoudjou-Pekam; Ginette Irma Kame-Ngasse; Jean Bosco Taya-Fokou; Chris Andre Mbongue Mikangue; Raoul Kenfack-Momo; Donatien Serge Mbaga; Arnol Bowo-Ngandji; Cyprien Kengne-Ndé; Seraphine Nkie Esemu; Richard Njouom; Lucy Ndip Journal: World J Crit Care Med Date: 2022-07-09
Authors: Tiffany L Turner; Benjamin T Kopp; Grace Paul; Lindsay C Landgrave; Don Hayes; Rohan Thompson Journal: Clinicoecon Outcomes Res Date: 2014-04-25